DrugPatentWatch Database Preview
Aztreonam - Generic Drug Details
What are the generic drug sources for aztreonam and what is the scope of aztreonam freedom to operate?
Aztreonam
is the generic ingredient in four branded drugs marketed by Gilead, Bristol Myers Squibb, Fresenius Kabi Usa, and West-ward Pharms Int, and is included in five NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are eight drug master file entries for aztreonam. Three suppliers are listed for this compound.
Summary for aztreonam
| US Patents: | 4 |
| Tradenames: | 4 |
| Applicants: | 4 |
| NDAs: | 5 |
| Drug Master File Entries: | 8 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 48 |
| Clinical Trials: | 47 |
| Patent Applications: | 7,544 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for aztreonam |
| DailyMed Link: | aztreonam at DailyMed |
Pharmacology for aztreonam
| Ingredient-type | Monobactams |
| Drug Class | Monobactam Antibacterial |
Medical Subject Heading (MeSH) Categories for aztreonam
Synonyms for aztreonam
| (2S,3S)-3-((Z)-2-(2-ammoniothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-methyl-4-oxoazetidine-1-sulfonate |
| (2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate |
| (2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam) |
| (2S,3S)-3-[(2Z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-methyl-4-oxoazetidine-1-sulfonate |
| (2S,3S)-3-[[(2Z)-2-(2-ammonio-4-thiazolyl)-2-(2-carboxypropan-2-yloxyimino)-1-oxoethyl]amino]-2-methyl-4-oxo-1-azetidinesulfonate |
| (2S,3S)-3-[[(2Z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-methyl-1-oxidanyl-1-oxidanylidene-propan-2-yl)oxyimino-ethanoyl]amino]-2-methyl-4-oxidanylidene-azetidine-1-sulfonate |
| (Z)-2-((((2-Amino-4-thiazolyl)(((2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid |
| (Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3- azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid |
| [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid |
| 110A380 |
| 2-((((E)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid |
| 2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid |
| 2-(((Z)-(1-(2-Aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid |
| 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid |
| 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid |
| 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid |
| 2-[(Z)-[1-(2-aminothiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic acid |
| 2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic Acid |
| 2-[1-(2-Amino-thiazol-4-yl)-1-((2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(Z)-ylideneaminooxy]-2-methyl-propionic acid |
| 78110-38-0 |
| A839338 |
| AB2000129 |
| AC-4330 |
| AC1NX3U2 |
| AK-41883 |
| AKOS015840157 |
| AKOS015961777 |
| AKOS026750006 |
| Ambap78110-38-0 |
| AN-12074 |
| Antibiotic squibb 26,776 |
| AS-13760 |
| Az-threonam |
| Azactam |
| Azactam (TN) |
| AZACTAM IN PLASTIC CONTAINER |
| Azetreonam |
| Azonam |
| Azthreonam |
| Aztreon |
| Aztreonam (Azactam, Cayston) |
| Aztreonam (JP17/USP/INN) |
| Aztreonam [USAN:INN:BAN:JAN] |
| Aztreonam [USAN:USP:INN:BAN:JAN] |
| Aztreonam lysine |
| Aztreonam, analytical standard |
| Aztreonam, pharmaceutical secondary standard; traceable to USP |
| Aztreonam, United States Pharmacopeia (USP) Reference Standard |
| Aztreonamum |
| Aztreonamum [Latin] |
| BC208259 |
| BCP9000372 |
| BCPP000356 |
| BDBM50240480 |
| BIDD:GT0765 |
| BPBio1_000121 |
| BRD-K62607865-001-03-0 |
| BRN 3577211 |
| BSPBio_000109 |
| C06840 |
| C13H17N5O8S2 |
| Cayston |
| CC-24234 |
| CCG-220185 |
| CHEBI:161680 |
| CHEMBL158 |
| Corus 1020 |
| CS-1902 |
| D00240 |
| D0F2XV |
| DB00355 |
| Dynabiotic |
| E-Aztreonam |
| EINECS 278-839-9 |
| G2B4VE5GH8 |
| HMS1568F11 |
| HMS2090K09 |
| HMS2095F11 |
| HY-B0129 |
| J10266 |
| LS-121219 |
| MFCD00072145 |
| MLS003915628 |
| MLS006011974 |
| MolPort-003-886-345 |
| Monobactam |
| Monobactam, SQ 26776, Squibb 26776, Aztreonam |
| Monobactam;SQ 26776;Squibb 26776;Azactam;Cayston |
| NCGC00179656-01 |
| Nebactam |
| NSC 646279 |
| NSC-646279 |
| NSC646279 |
| Prestwick_914 |
| Prestwick2_000185 |
| Prestwick3_000185 |
| Primbactam |
| Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2-alpha,3-beta(Z)))- |
| Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(Z)))- |
| Propanoic acid, 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl- |
| PubChem13620 |
| RP18114 |
| S1505 |
| SCHEMBL37511 |
| SMR002204030 |
| SMR004703537 |
| SO-26776 |
| SQ 26,776 |
| SQ 26776 |
| SQ-26,776 |
| SQ-26776 |
| Squibb 26,776 |
| Squibb 26776 |
| SR-01000841814 |
| SR-01000841814-2 |
| UNII-G2B4VE5GH8 |
| Urobactam |
| WZPBZJONDBGPKJ-VEHQQRBSSA-N |
| ZINC12503091 |
US Patents and Regulatory Information for aztreonam
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | AZACTAM | aztreonam | INJECTABLE;INJECTION | 050580-002 | Dec 31, 1986 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| West-ward Pharms Int | AZTREONAM | aztreonam | INJECTABLE;INJECTION | 065286-002 | Mar 23, 2011 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Bristol Myers Squibb | AZACTAM IN PLASTIC CONTAINER | aztreonam | INJECTABLE;INJECTION | 050632-003 | May 24, 1989 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for aztreonam
Supplementary Protection Certificates for aztreonam
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0030 | France | ➤ Sign Up | PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/543/001 DU 20090921; REGISTRATION NO/DATE AT EEC: EU/1/09/543/001 DU 20090921 |
| 2011 00021 | Denmark | ➤ Sign Up | |
| C/GB11/049 | United Kingdom | ➤ Sign Up | PRODUCT NAME: AZTREONAM LYSINE; REGISTERED: UK EU/1/09/543/001 20090921 |
| 90027-1 | Sweden | ➤ Sign Up | PRODUCT NAME: AZTREONAMLYSIN; REG. NO/DATE: EU/1/09/543/01 20090921 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: